Review
Biochemistry & Molecular Biology
Mirella Russo, Matteo A. De Rosa, Dario Calisi, Stefano Consoli, Giacomo Evangelista, Fedele Dono, Matteo Santilli, Alberto Granzotto, Marco Onofrj, Stefano L. Sensi
Summary: Migraine is a common neurological disorder that affects the quality of life of patients. The long-term impact of drugs used to treat migraine on cognition and neurodegeneration is not consistently evaluated. Different drugs used for migraine treatment have distinct effects on the central nervous system and should be carefully evaluated when prescribing treatment. The conflicting results in the relationship between migraine and dementia need to consider the pharmacological regimens used.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Pharmacology & Pharmacy
Farzin Zobdeh, Aziza Ben Kraiem, Misty M. Attwood, Vladimir N. Chubarev, Vadim V. Tarasov, Helgi B. Schioth, Jessica Mwinyi
Summary: Migraine is a prevalent disease globally and limited therapy response requires individually adjusted treatment. The pharmaceutical development for acute and chronic migraine has significantly intensified in recent years, with an expansion of drug targets and increased number of clinical trials.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Article
Clinical Neurology
Justin L. Hoskin, Terry D. Fife
Summary: The CGRP medications appear to be a decent treatment option for vestibular migraine (VM), with most patients experiencing some level of symptom improvement.
FRONTIERS IN NEUROLOGY
(2022)
Article
Medicine, General & Internal
David Moreno-Ajona, Maria Dolores Villar-Martinez, Peter J. Goadsby
Summary: Migraine is a debilitating disease and new treatment options are necessary due to the issues with existing medications. The latest generation of CGRP pathway-targeting drugs have shown efficacy, safety, and tolerability in clinical trials. This article reviews the clinical trials of existing and new drugs.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Clinical Neurology
Rikki Mangrum, Maya T. Gerstein, Calvin J. J. Hall III, Dawn C. Buse, Carrie R. Houts, James S. McGinley, Kelly P. McCarrier, Richard B. Lipton, R. J. Wirth
Summary: Through qualitative interviews with 40 patients with migraine, it was found that the most important treatment outcomes for patients are pain relief and absence of pain. Patients also prioritize reducing the frequency, severity, and duration of migraine attacks in preventive treatment. Personal expectations and experiences of migraine treatment also influence patients' assessment of treatment outcomes.
Review
Clinical Neurology
Babasola O. Okusanya, Breanne E. Lott, John Ehiri, Jean McClelland, Cecilia Rosales
Summary: This review assessed the effectiveness and safety of medical cannabis (MC) for treating migraines in adults. The results showed that MC significantly reduced nausea and vomiting associated with migraine attacks, as well as the number of migraine days and frequency. Compared to non-cannabis products, MC was more effective in reducing migraines. However, its use was associated with medication overuse headaches and mild adverse events. More well-designed experimental studies are needed to further support this hypothesis.
FRONTIERS IN NEUROLOGY
(2022)
Article
Operations Research & Management Science
Chi-Wei Su, Xi Yuan, Xuefeng Shao, Nicoleta-Claudia Moldovan
Summary: China actively formulates the development plans of new energy vehicles to promote sustainability in the automotive industry. The study finds that the current development of new energy vehicles has minimal environmental benefits due to the industry's growth and need for technological improvement.
ANNALS OF OPERATIONS RESEARCH
(2023)
Article
Clinical Neurology
Stephanie J. Nahas, Nada Hindiyeh, Deborah I. Friedman, Nada Elbuluk, Donald J. Kellerman, Pamela K. Foreman, Peter Schmidt
Summary: The study aimed to evaluate the safety and tolerability of M207 during long-term use for the treatment of migraine attacks. Results showed that most participants experienced cutaneous adverse reactions, with the majority of reactions being mild.
JOURNAL OF HEADACHE AND PAIN
(2021)
Review
Neurosciences
Jamir Pitton Rissardo, Ana Leticia Fornari Caprara
Summary: CGRP antagonists are a class of medications used for the prevention and treatment of migraines by acting as antagonists of the CGRP receptor or ligand. The second and third generations of gepants have been clinically validated and shown to be effective for acute and preventive treatment. However, further research is needed to explore the potential long-term side effects of these drugs.
Review
Clinical Neurology
Christopher Gottschalk, Dawn C. Buse, Michael J. Marmura, Bradley Torphy, Jelena M. Pavlovic, Paula K. Dumas, Nim Lalvani, Andrew Blumenfeld
Summary: This review study analyzes clinical trial data and finds that some approved migraine preventive therapies can bring significant improvements in the early stages of treatment, such as reducing the frequency and severity of migraine attacks. However, the available evidence for early onset prevention of migraine is limited.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS
(2022)
Article
Clinical Neurology
E. Anne MacGregor, Mika Komori, John Henry Krege, Simin Baygani, Maurice Vincent, Jelena Pavlovic, Hisaka Igarashi
Summary: Lasmiditan treatment of perimenstrual migraine attacks was associated with freedom from migraine-related head pain at two hours, early onset of efficacy, and sustained efficacy.
Review
Clinical Neurology
Meritxell Urtecho, Brittin Wagner, Zhen Wang, Juliana H. H. Van der Pluym, Rashmi B. Halker B. Singh, Jane Noyes, Mary E. E. Butler, Mohammad Hassan Murad
Summary: This study aimed to identify the preferred features of migraine treatment and the treatment outcomes most valued by patients. The findings revealed that patients preferred features such as shared decision-making, tailored approach, trust in healthcare professionals, and diversity of treatment options. Patients also preferred nonpharmacologic treatment, high effectiveness, rapidity of action, and self-management/self-delivery options. The treatment outcomes that had high value to patients included maintaining or improving function and avoiding side effects and non-headache symptoms.
Article
Clinical Neurology
Andrew Blumenfeld, Stewart J. Tepper, Rashna Khanna, Erin Doty, Maurice Vincent, Sheila I. Miller
Summary: Based on the analysis of clinical trial data and post-marketing surveillance, it was found that there is a potential risk of serotonin syndrome (SS) with lasmiditan treatment. Clinicians should be aware of the clinical symptomatology and diagnostic criteria of SS to recognize rare instances that may occur with lasmiditan.
FRONTIERS IN NEUROLOGY
(2023)
Review
Medicine, General & Internal
Raffaele Ornello, Eleonora De Matteis, Chiara Di Felice, Valeria Caponnetto, Francesca Pistoia, Simona Sacco
Summary: Menstrual migraine and perimenopausal migraine are distinct clinical entities influenced by female reproductive milestones, with treatment options including long-acting triptans, combination therapy, and hormone treatments. Future research should focus on the interaction between female sex hormones and the mechanisms of migraine pathogenesis.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Clinical Neurology
Hsiangkuo Yuan, John G. Curran, Scott W. Keith, Mary M. Hopkins, Stephen D. Silberstein
Summary: The study evaluated the efficacy and safety of IV ibuprofen for acute migraine treatment. While the primary endpoint was not met, there was significant pain relief within 2 hours post-treatment with IV ibuprofen compared to placebo. Adverse events were minimal, suggesting that IV ibuprofen may be a safe and effective option for acute migraine treatment. Further studies with larger sample sizes are needed for confirmation.